Figure 1

Bosutinib inhibit KRAS mutant cell migration and invasion but not KRAS wildtype cells. The serum-starved KRAS (A & C) mutant and (B & D) wildtype cells were trypsinized and seeded in the upper chamber of the Transwell (8 mm pore, A &B) or Matrigel™ (C & D), in the presence of DMSO or bosutinib at various concentrations (0.1, 0.5 and 1 μM). Medium containing 10% FBS and DMSO or bosutinib (0.1, 0.5 and 1 μM) was used as chemoattractant in the lower chamber. The migrated or invaded cells were fixed and stained with 0.5% crystal violet blue after 6 h and 24 h respectively. Cells that migrated or invaded across the filter were counted. Experiments were carried out in duplicates with five random fields counted. The percentage of migrated or invaded cells was expressed with respect to the DMSO treated cells.